BR112022008919A2 - Composto e método para tratamento de distúrbios psiquiátrico ou neurológico - Google Patents

Composto e método para tratamento de distúrbios psiquiátrico ou neurológico

Info

Publication number
BR112022008919A2
BR112022008919A2 BR112022008919A BR112022008919A BR112022008919A2 BR 112022008919 A2 BR112022008919 A2 BR 112022008919A2 BR 112022008919 A BR112022008919 A BR 112022008919A BR 112022008919 A BR112022008919 A BR 112022008919A BR 112022008919 A2 BR112022008919 A2 BR 112022008919A2
Authority
BR
Brazil
Prior art keywords
psychiatric
treatment
neurological disorders
compound
compounds
Prior art date
Application number
BR112022008919A
Other languages
English (en)
Inventor
Rands Peter
Knight George
Chubb Richard
Londesbrough Derek
Benway Tiffanie
Joel Zelah
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916210.6A external-priority patent/GB201916210D0/en
Priority claimed from GBGB1917320.2A external-priority patent/GB201917320D0/en
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Publication of BR112022008919A2 publication Critical patent/BR112022008919A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTO E MÉTODO PARA TRATAMENTO DE DISTÚRBIOS PSIQUIÁTRICO OU NEUROLÓGICO. A presente invenção relata para compostos da fórmula 1, ou sais farmaceuticamente aceitáveis do mesmo, bem como composições compreendendo tais sais. Esses compostos e composições têm uso no tratamento de distúrbios psiquiátrico ou neurológico. Os compostos da fórmula I compreendem pelo menos um átomo de deutério na posição e consequentemente melhoram a biodisponibilidade oral em relação aos análogos dipróticos
BR112022008919A 2019-11-07 2020-11-09 Composto e método para tratamento de distúrbios psiquiátrico ou neurológico BR112022008919A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1916210.6A GB201916210D0 (en) 2019-11-07 2019-11-07 High purity tryptamines and methods of synthesis thereof
GBGB1917320.2A GB201917320D0 (en) 2019-11-28 2019-11-28 Novel compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
PCT/EP2020/081502 WO2021089872A1 (en) 2019-11-07 2020-11-09 Compounds

Publications (1)

Publication Number Publication Date
BR112022008919A2 true BR112022008919A2 (pt) 2022-08-09

Family

ID=75849570

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008919A BR112022008919A2 (pt) 2019-11-07 2020-11-09 Composto e método para tratamento de distúrbios psiquiátrico ou neurológico

Country Status (18)

Country Link
US (4) US11643390B2 (pt)
EP (3) EP4180037A1 (pt)
JP (3) JP7422473B2 (pt)
KR (2) KR20230142817A (pt)
CN (2) CN114829340B (pt)
AU (2) AU2020378647B2 (pt)
BR (1) BR112022008919A2 (pt)
CA (2) CA3160337C (pt)
DK (1) DK3844147T3 (pt)
ES (2) ES2940811T3 (pt)
HR (2) HRP20230281T1 (pt)
HU (2) HUE059403T2 (pt)
IL (2) IL292753B2 (pt)
MX (1) MX2022005399A (pt)
NZ (1) NZ788543A (pt)
PL (2) PL3844147T3 (pt)
PT (2) PT3844147T (pt)
WO (2) WO2021089873A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20230281T1 (hr) 2019-11-07 2023-04-28 Small Pharma Ltd Postupak sinteze
JP2023513680A (ja) 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
KR20230012501A (ko) 2020-05-19 2023-01-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
WO2021116503A2 (en) * 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
KR102589605B1 (ko) * 2020-06-02 2023-10-13 스몰 파마 엘티디 중수소화 또는 부분 중수소화 n,n-디메틸트립타민 화합물을 포함하는 치료용 조성물
KR20230024378A (ko) 2020-06-12 2023-02-20 벡클리 싸이테크 리미티드 5-메톡시-n, n-디메틸트립타민의 벤조에이트 염을 포함하는 조성물
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
IL310296A (en) * 2021-07-22 2024-03-01 Gh Res Ireland Limited A method for the preparation of a tryptamine derivative
EP4122916A1 (en) * 2021-07-22 2023-01-25 GH Research Ireland Limited Method for preparing an organic compound
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023089132A1 (en) 2021-11-18 2023-05-25 Small Pharma Ltd Injectable and inhalable formulations
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US20240101514A1 (en) * 2022-08-19 2024-03-28 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024079314A1 (en) 2022-10-13 2024-04-18 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
WO1993000333A1 (en) * 1991-06-21 1993-01-07 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
CA2412905A1 (en) 2000-06-16 2001-12-27 Rtp Pharma Inc. Improved injectable dispersions of propofol
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
AU2007310949A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) * 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
AU2008283903B2 (en) * 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
SG11201504709PA (en) * 2013-03-14 2015-07-30 Dart Neuroscience Llc Substituted pyridine and pyrazine compounds as pde4 inhibitors
US10336703B2 (en) 2015-05-12 2019-07-02 Council Of Scientific And Industrial Research Process for the synthesis of ivacaftor and related compounds
US20200030309A1 (en) * 2016-09-29 2020-01-30 The Regents Of The University Of California Compounds for increasing neural plasticity
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
WO2018195455A1 (en) 2017-04-20 2018-10-25 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3713568A1 (en) * 2017-10-26 2020-09-30 Consejo Superior de Investigaciones Cientificas (CSIC) Combination product for the treatment of neurological and/or psychiatric disorders
US11117870B2 (en) 2017-11-01 2021-09-14 Drexel University Compounds, compositions, and methods for treating diseases
CN114555078A (zh) 2019-02-22 2022-05-27 Gh研究爱尔兰有限公司 用于治疗抑郁症的5-甲氧基-n,n-二甲基色胺(5-meo-dmt)
CN114423422A (zh) 2019-02-22 2022-04-29 Gh研究爱尔兰有限公司 用于治疗精神障碍的含有5-甲氧基-n,n-二甲基色胺(5-meo-dmt)的组合物
AU2020229779A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
AU2020228289A1 (en) * 2019-02-27 2021-09-09 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
HRP20230281T1 (hr) 2019-11-07 2023-04-28 Small Pharma Ltd Postupak sinteze
CN111072492A (zh) * 2019-11-29 2020-04-28 浙江工业大学 一种合成3,4-二氯-2-氨基-5-氟联苯的方法
JP2023513680A (ja) 2020-02-04 2023-04-03 マインドセット ファーマ インコーポレイテッド 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体
KR20230012501A (ko) 2020-05-19 2023-01-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
WO2022031566A1 (en) 2020-08-05 2022-02-10 Universitatsspital Basel Intravenous dmt administration method for dmt-assisted psychotherapy
CN115701994B (zh) 2020-08-28 2024-03-08 赛本英国有限公司 可注射制剂
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
KR20230079351A (ko) 2020-10-02 2023-06-07 사이빈 아이알엘 리미티드 흡입에 의한 심리치료제(psychedelic) 약물의 전달을 위한 방법 및 이 방법을 수행하기 위한 시스템
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Also Published As

Publication number Publication date
JP7423131B2 (ja) 2024-01-29
CN114829340B (zh) 2023-12-12
IL292754A (en) 2022-07-01
KR20230142817A (ko) 2023-10-11
WO2021089872A1 (en) 2021-05-14
US20210395201A1 (en) 2021-12-23
HRP20230281T1 (hr) 2023-04-28
EP4180037A1 (en) 2023-05-17
CN114829341B (zh) 2024-03-08
MX2022005399A (es) 2022-07-05
IL292753B1 (en) 2023-09-01
CN114829341A (zh) 2022-07-29
HUE059403T2 (hu) 2022-11-28
US20230250059A1 (en) 2023-08-10
JP2023500532A (ja) 2023-01-06
EP3873883B1 (en) 2022-12-21
ES2940811T3 (es) 2023-05-11
JP2022546635A (ja) 2022-11-04
KR20220082092A (ko) 2022-06-16
PL3844147T3 (pl) 2022-07-18
NZ788543A (en) 2022-10-28
US11578039B2 (en) 2023-02-14
CA3160334A1 (en) 2021-05-14
AU2020381103B2 (en) 2022-08-11
HRP20220797T1 (hr) 2022-10-14
CA3160337A1 (en) 2021-05-14
JP2024028798A (ja) 2024-03-05
CA3160337C (en) 2023-08-29
PT3844147T (pt) 2022-07-04
JP7422473B2 (ja) 2024-01-26
WO2021089873A1 (en) 2021-05-14
AU2020378647A1 (en) 2022-06-09
DK3844147T3 (da) 2022-07-04
IL292753A (en) 2022-07-01
PL3873883T3 (pl) 2023-05-08
US20220281818A1 (en) 2022-09-08
HUE061482T2 (hu) 2023-07-28
EP3873883A1 (en) 2021-09-08
CA3160334C (en) 2024-04-30
AU2020378647B2 (en) 2023-06-15
ES2920681T3 (es) 2022-08-08
EP3844147B1 (en) 2022-04-06
PT3873883T (pt) 2023-03-24
CN114829340A (zh) 2022-07-29
AU2020381103A1 (en) 2022-06-09
EP3844147A1 (en) 2021-07-07
IL292753B2 (en) 2024-01-01
US11643390B2 (en) 2023-05-09
US20230167056A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
BR112022008919A2 (pt) Composto e método para tratamento de distúrbios psiquiátrico ou neurológico
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020009372A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2021006283A (es) Derivados heteroaromáticos para uso como regulador, método de preparación de los mismos y uso de los mismos.
PH12020552017A1 (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2020007265A (es) Derivados de rapamicina.
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
MD4626C1 (ro) Derivaţi de tamoxifen pentru tratamentul afecţiunilor neoplazice, în special cu nivel înalt de proteină HER2
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
SG10201806809QA (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA202091604A1 (ru) Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
MY197561A (en) Composition for increasing expression of pgc-1?
BRPI0713333A2 (pt) Potencializador de terapia de radiação
BRPI0519210A2 (pt) macrocilos de sulfonamido como inibidores de tie2 e os sais destes, uma composiÇço farmacÊutica compreendendo estes compostos, o mÉtodo de preparar e o uso destes
BRPI0606284A2 (pt) derivados de aril 1,4 pirazina substituìda
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
BR112022010943A2 (pt) Análogos de nucleosídeos substituídos como inibidores de prmt5
MX2019015371A (es) Derivados de dihidro-pirrolo-piridina.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: SMALL PHARMA LTD (GB)